Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00786396 · ClinicalTrials.gov registry record · NA
Directly Observed Therapy for Community-Released HIV+ Prisoners
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 151
- Enrollment target
NCT00786396: Completed NA study, sponsored by Yale University.
NCT00786396 is a NA study that has completed, run by Yale University. The registered enrollment target is 151 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00786396, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 151 participants
- Enrollment target
Study Summary
The aim of this study is to develop effective interventions for HIV-infected prisoners who are released to the community. The intervention that we will study will be directly observed therapy (DAART/DOT) and we will compare this to the current standard of care that involves self-administered therapy (SAT). All subjects will get transitional case management and all subjects with a prior history of opiate dependence will be offered opiate substitution therapy (buprenorphine or methadone). Hypotheses: * At the end of six months those receiving DAART will have a higher level of adherence to HAART as compared to the SAT group. * The DAART Intervention will result in subjects having lower viral loads and higher CD4 counts as compared to the SAT group. * At the end of six months, the DAART group will have a lower rate of recidivism to jail/prison as compared to the SAT group. * Over the year, the DAART group will be more likely to make repeated primary HIV care visits than the SAT group.
Interventions
- BEHAVIORAL Directly administered antiretroviral therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2004-07 |
| Est. Completion | 2010-12 |
| Phase | NA |
What the finished NCT00786396 record still lists
NCT00786396 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Directly administered antiretroviral therapy is the first listed.
NCT00786396 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00786396 about?
NCT00786396 is a clinical study titled "Directly Observed Therapy for Community-Released HIV+ Prisoners". The aim of this study is to develop effective interventions for HIV-infected prisoners who are released to the community. The intervention that we will study will be directly observed therapy (DAART/DOT) and we will compare this to the current standard of care that involves self-administered therapy...
What is the current status of trial NCT00786396?
This trial is currently completed. It is a NA study. The enrollment target is 151 participants. The study started on 2004-07. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00786396?
The interventions under investigation include: Directly administered antiretroviral therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00786396?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00786396's enrollment target sits among peer trials
151 661st of 2000 higher than 1,340 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia